Intravenous Erythropoietin in Patients With ST-Segment Elevation Myocardial Infarction
REVEAL: A Randomized Controlled Trial

Samer S. Najjar, MD
Sunil V. Rao, MD
Chiara Melloni, MD, MHS
Subha V. Raman, MD
Thomas J. Povsic, MD, PhD
Laura Melton, PhD
Gregory W. Barsness, MD
Kristi Prather, MPH
John F. Heitner, MD
Rakhi Kilaru, MS
Luis Gruberg, MD
Vic Hasselblad, PhD
Adam B. Greenbaum, MD
Manesh Patel, MD
Raymond J. Kim, MD
Mark Talan, MD, PhD
Luigi Ferrucci, MD, PhD
Dan L. Longo, MD
Edward G. Lakatta, MD
Robert A. Harrington, MD
for the REVEAL Investigators

Context Acute ST-segment elevation myocardial infarction (STEMI) is a leading cause of morbidity and mortality. In experimental models of MI, erythropoietin reduces infarct size and improves left ventricular (LV) function.

Objective To evaluate the safety and efficacy of a single intravenous bolus of epoetin alfa in patients with STEMI.

Design, Setting, and Patients A prospective, randomized, double-blind, placebo-controlled trial with a dose-escalation safety phase and a single dose (60,000 U of epoetin alfa) efficacy phase; the Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction (REVEAL) trial was conducted at 28 US sites between October 2006 and February 2010, and included 222 patients with STEMI who underwent successful percutaneous coronary intervention (PCI) as a primary or rescue reperfusion strategy.

Intervention Participants were randomly assigned to treatment with intravenous epoetin alfa or matching saline placebo administered within 4 hours of reperfusion.

Main Outcome Measure Infarct size, expressed as percentage of LV mass, assessed by cardiac magnetic resonance (CMR) imaging performed 2 to 6 days after study medication administration (first CMR) and again 12±2 weeks later (second CMR).

Results In the efficacy cohort, the infarct size did not differ between groups on either the first CMR scan (n=136; 15.8% LV mass [95% confidence interval {CI}, 13.3-18.2% LV mass] for the epoetin alfa group vs 15.0% LV mass [95% CI, 12.6-17.3% LV mass] for the placebo group; P=.67) or on the second CMR scan (n=124; 10.6% LV mass [95% CI, 8.4-12.8% LV mass] vs 10.4% LV mass [95% CI, 8.5-12.3% LV mass], respectively; P=.89). In a prespecified analysis of patients aged 70 years or older (n=21), the mean infarct size within the first week (first CMR) was larger in the epoetin alfa group (19.9% LV mass; 95% CI, 14.0-25.7% LV mass) than in the placebo group (11.7% LV mass; 95% CI, 7.2-16.1% LV mass) (P=.03). In the safety cohort, of the 125 patients who received epoetin alfa, the composite outcome of death, MI, stroke, or stent thrombosis occurred in 5 (4.0%; 95% CI, 1.31%-9.09%) but in none of the 97 who received placebo (P=.04).

Conclusions In patients with STEMI who had successful reperfusion with primary or rescue PCI, a single intravenous bolus of epoetin alfa within 4 hours of PCI did not reduce infarct size and was associated with higher rates of adverse cardiovascular events. Subgroup analyses raised concerns about an increase in infarct size among older patients.

Trial Registration clinicaltrials.gov Identifier: NCT00378352
JAMA. 2011;305(18):1863-1872
www.jama.com

©2011 American Medical Association. All rights reserved.
farct zone and the noninfarcted myocardium). Both are strongly associated with heart failure and death. Risk factors for infarct expansion and LV remodeling include infarct size, extent of apoptosis, anterior location of the infarct, severe microvascular obstruction, and older age. Given the global burden of ischemic heart disease and heart failure, therapies that limit infarct size and attenuate or reverse LV remodeling are needed.

Erythropoietin is a 165-amino acid glycoprotein hormone whose production and secretion are regulated by tissue oxygen levels. Beyond its effects on red blood cell production, erythropoietin exhibits pleiotropic effects in cells and tissues, including stimulation of angiogenesis and protection against apoptosis. Furthermore, erythropoietin receptors have been identified on endothelial cells and cardiomyocytes. Preclinical studies have shown that erythropoietin plays a cardioprotective role in various experimental models of myocardial ischemia and ischemia reperfusion. In these investigations, erythropoietin was associated with significant reductions in infarct size and improvements in LV function that were partly attributed to its antiapoptotic and angiogenic properties.

To determine whether erythropoietin has similar cardioprotective effects in a clinical setting, we performed the Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction (REVEAL) trial, which evaluated the safety and effect on infarct size of a single intravenous bolus of recombinant human erythropoietin (epoetin alfa) in patients with STEMI who have undergone successful primary or rescue percutaneous coronary intervention (PCI).

METHODS

The REVEAL trial was a multicenter, phase 2, randomized, double-blind, placebo-controlled clinical trial that evaluated the safety and efficacy of a single intravenous bolus of epoetin alfa in patients with STEMI. The design and rationale of the REVEAL trial have been published. Briefly, the study consisted of a dose-escalation phase and an efficacy phase (Figure 1). During the dose-escalation phase, 3 doses of epoetin alfa (15,000 U, 30,000 U, and 60,000 U) were sequentially evaluated. These doses were chosen with guidance from the US Food and Drug Administration to balance safety concerns with the relatively high doses of erythropoietin used in preclinical studies. Patients were randomly allocated in a 2 to 1 ratio to each dose of epoetin alfa or placebo, respectively. Dose escalation was guided by an independent data and safety monitoring board, which reviewed clinical and safety data at 2 time points for each dose cohort.

Based on the study design, the highest planned dose of epoetin alfa that was deemed acceptable by the data and safety monitoring board was used in the efficacy phase, in which participants were randomly allocated in a 1 to 1 ratio to epoetin alfa or placebo. The REVEAL study was reviewed and approved by the MedStar Research Institute’s institutional review board and by the respective institutional review boards of the participating sites. Written informed consent was obtained from all participants or their legally authorized representatives.

In accordance with guidelines from the National Institutes of Health, self-reported information on race and ethnicity was collected from all study participants. Categories were defined by the study investigators and consisted of Hispanic/Latino or non-Hispanic/Latino for ethnicity and American Indian/Alaska Native, Asian, Native Hawaiian/Pacific Islander, other (which were later condensed into 1 category), white, or black/African American for race.

Eligibility Criteria, Randomization, and Study Medication

Study eligibility criteria are listed in eTable 1 at http://www.jama.com. Briefly, patients were eligible if they had acute STEMI with a Thrombolysis in Myocardial Infarction (TIMI) flow grade of 0 to 1 in a major epicardial artery or large branch vessel during index angiography and underwent successful primary or rescue PCI within 8 hours of onset of ischemic symptoms. To minimize confounding of the measurement of infarct size, patients with a history of LV dysfunction (LV ejection fraction [LVEF] ≤50%), MI, coronary artery bypass grafting, or revascularization in the territory of the culprit artery were excluded.

Eligible patients were randomly assigned to epoetin alfa or matching placebo according to the allocation ratio for each dosing cohort. Randomization was performed with a fixed-block randomization scheme using a Web-based application (WebEZ, Almac, Durham, North Carolina) fully integrated with drug supply management information. Randomization was stratified according to age (<70 years or ≥70 years) and infarct location (left anterior descending or non–left anterior descending coronary artery).

Study medication (epoetin alfa or matching saline placebo) was administered within 4 hours of successful primary or rescue PCI, defined as time of restoration of TIMI flow grade of 2 or greater in the infarct-related artery. During the initial phase of the REVEAL trial, epoetin alfa and matching placebo were provided free of charge by Centocor Ortho Biotech Clinical Affairs (Bridgewater, New Jersey). However, during the efficacy phase, the company elected to cease providing study medication, and the study sponsor (National Institute on Aging) purchased active study medication from Centocor Ortho Biotech and contracted with Florida Biologix, in Alachua, to manufacture matching placebo. All other treatments, including PCI techniques, were at the discretion of the treating physicians, who were encouraged to adhere to guideline recommendations for the management of patients with STEMI.

Cardiac Magnetic Resonance (CMR) Imaging

Patients underwent the first CMR 2 to 6 days after study medication administration and the second CMR 12 ± 2
weeks later. Each CMR examination consisted of (1) a cine CMR for assessment of LV volumes (end-systolic volume and end-diastolic volume), LV mass, and LV function quantified by LVEF and (2) a delayed contrast-enhanced CMR for assessment of infarct size. The values for LV end-systolic volume, LV end-diastolic
volume, and LV mass were indexed to body surface area (BSA). Deidentified CMR studies were analyzed at a core laboratory (Duke Cardiovascular Magnetic Resonance Center, Durham, North Carolina) by investigators masked to treatment assignment and clinical outcomes. Details of the imaging protocol have been published.18

Primary and Secondary End Points
The primary efficacy end point of the study was infarct size in the territory of the infarct-related artery, expressed as percentage of LV mass and measured by the first CMR (performed 2-6 days or 48-144 hours) after study medication administration. Secondary end points included infarct size, 3 LV remodeling parameters (LV end-systolic volume, LV end-diastolic volume, and LV mass, each indexed to BSA) and LV function (LVEF) measured by CMR 12±2 weeks after study medication administration (second CMR). The 3 LV remodeling parameters and LVEF measured on the first CMR also were examined.

Safety end points included vital signs, hemoglobin level, reticulocyte count, markers of cardiac injury, and clinical events including death, recurrent MI, unplanned PCI, arterial thrombotic events (stent thrombosis), venous thrombotic events (deep venous thrombus, pulmonary embolus), heart failure, and neurological events (stroke, transient ischemic attack).

Table 1. Baseline Characteristics of Study Patients

<table>
<thead>
<tr>
<th>Demographics</th>
<th>Total Cohort (N = 222)</th>
<th>Efficacy Cohort (N = 138)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age, mean (SD), y</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epoetin Alfa (n = 123)</td>
<td>Placebo (n = 99)</td>
<td>Epoetin Alfa (n = 68)</td>
</tr>
<tr>
<td>Female sex</td>
<td>23 (18.7)</td>
<td>21 (21.2)</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>4 (3.3)</td>
<td>4 (4.0)</td>
</tr>
<tr>
<td>Hispanic</td>
<td>4 (3.3)</td>
<td>7 (7.1)</td>
</tr>
<tr>
<td>Non-Hispanic</td>
<td>119 (96.7)</td>
<td>92 (92.9)</td>
</tr>
<tr>
<td>Weight, mean (SD), kg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epoetin Alfa (n = 123)</td>
<td>Placebo (n = 99)</td>
<td>Epoetin Alfa (n = 68)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Height, mean (SD), cm</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epoetin Alfa (n = 123)</td>
<td>Placebo (n = 99)</td>
<td>Epoetin Alfa (n = 68)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>58 (47.2)</td>
<td>53 (53.5)</td>
</tr>
<tr>
<td>Current smoker</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes</td>
<td>14 (11.4)</td>
<td>25 (25.3)</td>
</tr>
<tr>
<td>Baseline Medication Use</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clopidogrel</td>
<td>118 (95.9)</td>
<td>94 (94.9)</td>
</tr>
<tr>
<td>Aspirin</td>
<td>110 (91.0)</td>
<td>93 (93.9)</td>
</tr>
<tr>
<td>Heparin</td>
<td>108 (87.8)</td>
<td>86 (86.9)</td>
</tr>
<tr>
<td>Glycoprotein IIb/IIIa inhibitor</td>
<td>88 (71.5)</td>
<td>71 (71.7)</td>
</tr>
<tr>
<td>Patient Subgroups</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age category, y</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;70</td>
<td>103 (83.7)</td>
<td>81 (81.8)</td>
</tr>
<tr>
<td>≥70</td>
<td>20 (16.3)</td>
<td>18 (18.2)</td>
</tr>
<tr>
<td>Infarct-related artery</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonanterior</td>
<td>89 (72.4)</td>
<td>72 (72.7)</td>
</tr>
<tr>
<td>Anterior</td>
<td>34 (27.6)</td>
<td>27 (27.3)</td>
</tr>
</tbody>
</table>

©2011 American Medical Association. All rights reserved.
INTRANUSCULAR ERYTHROPOIETIN FOR ST-SEGMENT ELEVATION MI

farct size and time from symptom onset to study drug administration and between infarct size and time from study drug administration to first CMR. The primary outcome variable, infarct size expressed as percentage of LV mass measured on the first CMR, was compared between the 2 groups using the log-rank test, both with and without adjustment for age group (<70 vs 70 years), infarct-related artery location (left anterior descending vs non–left anterior descending), and enrollment phase.

Between-group comparisons for all other cardiac variables assessed by CMR were performed with analysis of variance for unadjusted analyses and with analysis of covariance for adjusted analyses. The adjusted analyses controlled for age group, infarct-related artery location, and enrollment phase. Adjustment for enrollment phase was performed to control for implicit differences that may exist between patients recruited in the dose-escalation phase and patients recruited in the efficacy phase. For cardiac variables measured on the second CMR, the adjusted models controlled for values of the same variables obtained on the first CMR. In addition, post hoc comparisons of changes from the first CMR to the second CMR in LV end-systolic volume, LV end-diastolic volume, and LV mass, each indexed to BSA, were performed with analysis of variance. The primary and secondary end points were further analyzed within the prespecified subgroups of patient age (<70 vs 70 years) and infarct-related artery location (left anterior descending vs non–left anterior descending).

Safety data were analyzed on an as-treated basis. The safety cohort comprised all patients who received study medication. Composite safety end points were added to the analysis plan at the suggestion of the data and safety monitoring board and were compared using the Fisher exact test with a mid-P value adjustment. One prespecified interim test of efficacy was performed using the Haybittle-Peto rule. Due to rounding, the interim analysis did not result in a penalty for the final α level. A 2-sided α level of .05 was considered statistically significant. P values were not adjusted for multiple comparisons. All statistical analyses were performed using SAS software version 9.2 (SAS Institute Inc, Cary, North Carolina).

RESULTS

Between October 2006 and November 2009, 223 participants at 22 of 28 US sites were enrolled into the study and randomized; 222 participants received study medication. Of these, 189 had the first CMR performed within 2 to 6 days after study drug administration (24 in the 15 000 U cohort; 27 in the 30 000 U cohort; and 138 in the 60 000 U combined efficacy cohort) (Figure 1). In the entire efficacy cohort, the median time from symptom onset to study drug administration was 6.3 hours (interquartile range, 5.0–7.6 hours) and the median time from study drug administration to first CMR was 66.3 hours (interquartile range, 50.2–118.7 hours). Most participants in this cohort (124/138; 89.9%) underwent follow-up CMR (second CMR) at 12±2 weeks. The last follow-up visit was conducted on February 12, 2010.

The baseline clinical characteristics of the total and efficacy cohorts, stratified by treatment assignment, are summarized in Table 1. The active medication (epoetin alfa) group and the placebo group were well matched, al-

©2011 American Medical Association. All rights reserved.
though the former had a significantly lower prevalence of diabetes mellitus, less use of rescue PCI, and a longer time from randomization until study drug administration.

**Efficacy Analyses**

Cardiac variables assessed by CMR in the efficacy cohort are shown in Table 2. The number of participants included in each efficacy analysis varied depending on CMR end point availability. The primary study end point of infarct size measured within 2 to 6 days after study medication administration was available for 136 of the 138 patients who underwent CMR and did not differ between the epoetin alfa and placebo groups in either the unadjusted analysis or the adjusted analysis, which controlled for age group, infarct-related artery location, and enrollment phase (Table 2 and Figure 2). There was no association between infarct size and time from study drug administration to first CMR ($r = –0.13$, $P = .14$). Infarct size measured at 12±2 weeks after the first CMR did not differ between groups in either the unadjusted or adjusted analyses. Adjusting for baseline clinical characteristics that differed between groups did not affect these findings. As with infarct size, infarct mass did not differ between groups at either time point.

The values for LVEF, LV end-systolic volume indexed to BSA, and LV end-diastolic volume indexed to BSA did not differ between groups in the unadjusted analysis at either time point (Table 2).

### Table 2. Left Ventricular (LV) Characteristics Assessed by Cardiac Magnetic Resonance (CMR) Imaging in the Efficacy Cohort

<table>
<thead>
<tr>
<th></th>
<th>First CMR (n = 138)</th>
<th>Second CMR (n = 124)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Epoetin Alfa</td>
<td>Placebo</td>
</tr>
<tr>
<td>Infarct size, % LV mass</td>
<td>(n = 68)</td>
<td>(n = 68)</td>
</tr>
<tr>
<td></td>
<td>15.8 (10.3) [13.3-18.2]</td>
<td>15.0 (10.0) [12.6-17.3]</td>
</tr>
<tr>
<td>Infarct mass, g</td>
<td>(n = 68)</td>
<td>(n = 68)</td>
</tr>
<tr>
<td></td>
<td>24.6 (18.9) [20.1-29.1]</td>
<td>21.1 (14.5) [17.6-24.5]</td>
</tr>
<tr>
<td>LV ejection fraction, %</td>
<td>(n = 68)</td>
<td>(n = 70)</td>
</tr>
<tr>
<td></td>
<td>48.2 (9.1) [46.0-50.4]</td>
<td>48.9 (8.7) [46.8-50.9]</td>
</tr>
<tr>
<td>LV volume indexed to BSA, mL/m²</td>
<td>(n = 65)</td>
<td>(n = 68)</td>
</tr>
<tr>
<td>End systolic</td>
<td>34.7 (14.7) [31.1-38.3]</td>
<td>32.6 (10.6) [30.1-35.1]</td>
</tr>
<tr>
<td>End diastolic</td>
<td>(n = 65)</td>
<td>(n = 68)</td>
</tr>
<tr>
<td></td>
<td>65.6 (18.2) [61.2-70.1]</td>
<td>63.4 (15.4) [59.7-67.0]</td>
</tr>
<tr>
<td>LV mass indexed to BSA, g/m²</td>
<td>(n = 68)</td>
<td>(n = 69)</td>
</tr>
<tr>
<td></td>
<td>74.2 (15.2) [70.6-77.8]</td>
<td>69.2 (13.0) [66.1-72.2]</td>
</tr>
</tbody>
</table>

Abbreviation: BSA, body surface area.

<table>
<thead>
<tr>
<th></th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>.89</td>
</tr>
<tr>
<td></td>
<td>.22</td>
</tr>
<tr>
<td></td>
<td>.67</td>
</tr>
<tr>
<td></td>
<td>.34</td>
</tr>
<tr>
<td></td>
<td>.44</td>
</tr>
<tr>
<td></td>
<td>.04</td>
</tr>
</tbody>
</table>

Values are expressed as mean (SD) [95% confidence interval] unless otherwise indicated. $P$ values are from unadjusted analysis.

Performed 2 to 6 days after study medication administration.

Performed 12±2 weeks after first CMR imaging.

**Figure 2. Comparison of Infarct Size Between Epoetin Alfa and Placebo Groups**

Boxes represent interquartile range, black-filled circles represent means, whiskers represent the minimum and maximum, and horizontal lines represent the median. Individual data points (open circles) are provided for the graph for patients aged 70 years or older due to the low sample sizes. For patients aged 70 years or older, the $P$ value is equal to .03 for the comparison of epoetin alfa with placebo for the first cardiac magnetic resonance (CMR) imaging. LV indicates left ventricular.
However, at 12 weeks, the adjusted analysis (which controlled for values of LV end-systolic volume indexed to BSA and LV end-diastolic volume indexed to BSA on initial CMR) showed that adjusted LV end-systolic volume indexed to BSA was 8.1% larger in the epoetin alfa group (n=61; 34.5 mL/m² [95% confidence interval (CI), 29.3-34.2 mL/m²]) than in the placebo group (n=62; 31.7 mL/m² [95% CI, 29.3-34.2 mL/m²]) (P = .04). Furthermore, adjusted LV end-diastolic volume indexed to BSA was 7.2% larger in the epoetin alfa group (n=61; 70.7 mL/m² [95% CI, 67.1-74.3 mL/m²]) than in the placebo group (n=62; 65.6 mL/m² [95% CI, 61.8-69.4 mL/m²]) (P = .01). Thus, in post hoc comparisons with the placebo group, the epoetin alfa group had a smaller decrease in LV end-systolic volume indexed to BSA from the first CMR to the second CMR (0.9 mL/m² [95% CI, −1.2 to 2.9 mL/m²] vs −1.9 mL/m² [95% CI, −3.7 to 0 mL/m²], respectively; P = .03) but a greater increase in LV end-diastolic volume indexed to BSA (5.8 mL/m² [95% CI, 2.7 to 8.9 mL/m²] vs 0.9 mL/m² [95% CI, −2.4 to 4.1 mL/m²], respectively; P = .03).

The only end point that differed significantly between groups in the unadjusted analysis was LV mass indexed to BSA (Table 2). On the first CMR, the mean LV mass indexed to BSA was 6.7% higher in the epoetin alfa group than in the placebo group (unadjusted P = .04; adjusted P = .03). This difference persisted at 12 weeks but was due to the difference in LV mass indexed to BSA on the first CMR because the change in LV mass indexed to BSA from the first CMR to second CMR did not differ between treatment groups (−6.2 g/m² [95% CI, −8.4 to −4.1 g/m²] for epoetin alfa vs −6.5 g/m² [95% CI, −8.3 to −4.7 g/m²] for placebo; P = .85).

### Subgroup Analyses

Infarct size did not differ between treatment groups according to infarct-related artery location in either the unadjusted or adjusted analysis within 2 to 6 days (first CMR) or at 12 weeks (second CMR). The interaction between treatment assignment and age group (P = .08) suggests that age group may modify the effect of epoetin alfa on infarct size. Infarct size did not differ between groups among patients younger than 70 years (Figure 2). However, among patients aged 70 years or older, the mean infarct size on the first CMR was 41.2% larger in the epoetin alfa group (15.0% LV mass [95% CI, 9.1-20.9% LV mass]) than in the placebo group (9.0% LV mass [95% CI, 4.9-13.0% LV mass]), although this difference was not statistically significant (unadjusted P = .12). The observed difference was mainly due to the difference in infarct size on the first CMR (adjusted P = .07 when controlling for infarct-related artery location and enrollment phase; adjusted P = .88 when controlling for the previously mentioned items plus the first CMR value of infarct size).

### Safety Analyses

Participants who received epoetin alfa had a higher incidence of adverse events (69/125 [55.2%; 95% CI, 46.05%-64.10%]) than those who received placebo (40/97 [41.2%; 95% CI, 31.33%-51.69%]; P = .04) (Table 3). These results were unchanged when the analyses were further adjusted for presence of diabetes mellitus, which was the only characteristic that significantly differed between the 2 groups (prevalence of 9.1% in the epoetin alfa group and 54.5% in the placebo group). Among patients aged 70 years or older, infarct size on the second CMR remained 40.0% larger in the epoetin alfa group (15.0% LV mass [95% CI, 9.1-20.9% LV mass]) than in the placebo group (9.0% LV mass [95% CI, 4.9-13.0% LV mass]), although this difference was not statistically significant (unadjusted P = .12). The observed difference was mainly due to the difference in infarct size on the first CMR (adjusted P = .07 when controlling for infarct-related artery location and enrollment phase; adjusted P = .88 when controlling for the previously mentioned items plus the first CMR value of infarct size).

#### Table 3. Clinical adverse events in the total and efficacy cohorts

<table>
<thead>
<tr>
<th>Events</th>
<th>Epoetin Alfa (n = 86)</th>
<th>Placebo (n = 75)</th>
<th>P Value</th>
<th>Epoetin Alfa (n = 86)</th>
<th>Placebo (n = 75)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Death</td>
<td>1 (0.8) [0.02-4.38]</td>
<td>0</td>
<td>.72</td>
<td>0</td>
<td>0</td>
<td>.00</td>
</tr>
<tr>
<td>Myocardial infarction (MI)*</td>
<td>2 (1.6) [0.19-5.66]</td>
<td>0</td>
<td>.35</td>
<td>1 (1.2) [0.03-6.31]</td>
<td>0</td>
<td>.73</td>
</tr>
<tr>
<td>Unstaged PCI</td>
<td>6 (4.8) [1.78-10.15]</td>
<td>0</td>
<td>.02</td>
<td>4 (4.7) [1.28-11.48]</td>
<td>0</td>
<td>.08</td>
</tr>
<tr>
<td>CABG</td>
<td>0</td>
<td>1 (1.0) [0.03-5.61]</td>
<td>.22</td>
<td>0</td>
<td>1 (1.3) [0.03-7.21]</td>
<td>.23</td>
</tr>
<tr>
<td>Stroke</td>
<td>1 (0.8) [0.02-4.38]</td>
<td>0</td>
<td>.72</td>
<td>0</td>
<td>0</td>
<td>.00</td>
</tr>
<tr>
<td>Sust thrombosis</td>
<td>3 (2.4) [0.50-6.85]</td>
<td>0</td>
<td>.17</td>
<td>2 (2.3) [0.08-8.15]</td>
<td>0</td>
<td>.36</td>
</tr>
<tr>
<td>LV thrombus</td>
<td>3 (2.4) [0.50-6.85]</td>
<td>2 (2.1) [0.25-7.25]</td>
<td>.83</td>
<td>2 (2.3) [0.28-8.15]</td>
<td>0</td>
<td>.36</td>
</tr>
<tr>
<td>New or worsening CHF</td>
<td>5 (4.0) [1.31-9.09]</td>
<td>2 (2.1) [0.25-7.25]</td>
<td>.36</td>
<td>2 (2.3) [0.28-8.15]</td>
<td>1 (1.3) [0.03-7.21]</td>
<td>.80</td>
</tr>
<tr>
<td>Any adverse event</td>
<td>69 (55.2) [46.05-64.10]</td>
<td>40 (41.2) [31.33-61.69]</td>
<td>.04</td>
<td>49 (57.0) [45.85-67.61]</td>
<td>31 (41.3) [30.08-53.30]</td>
<td>.05</td>
</tr>
<tr>
<td>Death, MI, or stroke, or stent thrombosis</td>
<td>5 (4.0) [1.31-9.09]</td>
<td>0</td>
<td>.04</td>
<td>2 (2.3) [0.28-8.15]</td>
<td>0</td>
<td>.36</td>
</tr>
<tr>
<td>Death, MI, or stroke</td>
<td>4 (3.2) [0.88-7.99]</td>
<td>0</td>
<td>.08</td>
<td>1 (1.2) [0.03-6.31]</td>
<td>0</td>
<td>.73</td>
</tr>
</tbody>
</table>

Abbreviations: CABG, coronary artery bypass graft; CHF, congestive heart failure; LV, left ventricular; PCI, percutaneous coronary intervention.

*Values are expressed as number (percentage) [95% confidence interval] unless otherwise indicated. Number of participants for cohorts given according to treatment received.

*Does not include index event.

*Includes events that occurred during the period between randomization and discharge or day 7, whichever came first.

*Includes events that occurred during the period between randomization and the second CMR.
participants also had a higher incidence of serious adverse events (25/125 [20.0%; 95% CI, 13.38%-28.09%]) than those who received placebo (10/97 [10.3%; 95% CI, 5.06%-18.14%]; P=.05). Of the 125 patients who received epoetin alfa, the composite outcome of death, MI, stroke, or stent thrombosis occurred in 5 (4.0%; 95% CI, 1.31%-9.09%) but in none of the 97 who received placebo (P=.04). Descriptions of these clinical events can be found in the eAppendix at http://www.jama.com.

There were no clinically meaningful differences between treatment groups in hemoglobin levels, reticulocyte counts, or blood pressure at the various time points assessed after administration of study medication (eTable 2 at http://www.jama.com), which likely reflects the fact that only a single infusion of epoetin alfa was administered. Similarly, there were no clinically meaningful differences between treatment groups in the changes in the levels of these variables from baseline or from the preceding time point.

**COMMENT**

In the REVEAL trial, a single bolus of intravenous epoetin alfa in patients with STEMI who underwent successful primary or rescue PCI failed to demonstrate a reduction in infarct size. There was a significant increase in infarct size in prespecified analyses among older patients. There was also a significant increase in the composite of cardiovascular adverse events that included stent thrombosis. Clinical interest in the use of erythropoietin as a cardioprotective agent emanated from a growing body of experimental evidence showing that erythropoietin’s nonerythropoietic effects include anti-inflammatory, anti-apoptotic, and angiogenic properties. In preclinical models, erythropoietin promotes neovascularization and induces mobilization of endothelial progenitor cells from bone marrow. In animal models of ischemic myocardial injury, erythropoietin was shown to reduce apoptotic cells, diminish cardiomyocyte loss, improve functional recovery, decrease infarct size, and attenuate infarct expansion.

**Other Clinical Trials**

Previous clinical studies evaluating the effects of erythropoietin on infarct size have yielded conflicting results. In 5 of these studies, infarct size was indirectly estimated from serial measurements of enzymatic markers of cardiac injury. In the HEBE III trial, a single dose of erythropoietin (60 000 U) within 3 hours of primary PCI in patients with STEMI reduced enzymatic infarct size by 6.7% (P=.06) but did not improve LVEF at 6 weeks. In a small pilot study, a single dose of erythropoietin (33 000 U) reduced enzymatic infarct size by 30%. However, in 3 other trials (1 in patients with non-STEMI, 1 in patients with STEMI who were treated with fibrinolysis, and 1 in patients with STEMI who underwent PCI), a single dose of erythropoietin (40 000 U, 40 000 U, and 50 U/kg, respectively) did not reduce enzymatic infarct size.

In 2 small studies that assessed infarct size with contrast-enhanced CMR (a powerful, validated tool that allows accurate and reproducible measurement of infarct size), erythropoietin did not affect infarct size at 4 days or at 6 months. Using CMR, the REVIVAL-3 (Regenerate Vital Myocardium by Vigorous Activation of Bone Marrow Stem Cells) study found that 3 daily doses of erythropoietin (33 000 U each) did not reduce infarct size at 5 days or at 6 months; 6-month LVEF also remained unimproved.

Taken together with the REVEAL trial, these results indicate that no clinical study of erythropoietin to date has shown any beneficial effect of erythropoietin on infarct size measured by CMR. Furthermore, the results in the subgroup of participants aged 70 years or older in the REVEAL trial suggest that erythropoietin may adversely affect infarct size in this high-risk population. Although this concerning finding should be interpreted with caution due to the small number of older patients enrolled in the REVEAL trial and the lack of multiplicity adjustment in the analyses, it suggests the need for added vigilance before enrolling older patients in any future trial evaluating erythropoietin in the setting of MI.

In the small pilot study (N=30) that reported a 30% reduction in enzymatic infarct size with erythropoietin, the erythropoietin treatment group had a greater decrease in LV end-systolic volume than the placebo group, and a similar increase in LV end-diastolic volume. Our larger study failed to replicate these observations. Instead, the epoetin alfa group in the REVEAL trial showed a smaller decrease in LV end-systolic volume indexed to BSA and a larger increase in LV end-diastolic volume indexed to BSA than the placebo group, suggesting a greater reliance on the Frank-Starling mechanism to augment stroke volume. Thus, administration of erythropoietin may be associated with adverse LV remodeling at 3 months.

In the REVEAL trial, we also found a significantly increased risk of death, recurrent MI, stroke, or stent thrombosis with erythropoietin, suggesting an increased thrombotic risk with erythropoietin in patients with STEMI. This is consistent with other studies involving erythropoietin in noncardiac populations. Chronic administration of erythropoietin can lead to increases in vasoconstriction, blood pressure, blood viscosity, and thrombotic risk. Some previous studies in patients with MI did not detect an increased risk of adverse events with erythropoietin. On the other hand, REVIVAL-3 observed an increased risk of death, recurrent MI, stroke, or target vessel revascularization in patients who received erythropoietin. Due to these conflicting safety findings, temporary withholding of erythropoietin in patients who are receiving this medication for labeled indications and who sustain an MI merits further study.

**Reconciling Animal and Clinical Studies**

The promising cytoprotective effects of erythropoietin observed in animal models have not been reproduced in clini-
cal studies of acute MI. It is conceivable that the effects of erythropoietin differ among species. For example, although erythropoietin reduced infarct size in a rodent model of coronary occlusion, it failed to do so in a porcine model. Moreover, the average infarct size in the REVEAL trial (approximately 15%-16%) was smaller than infarct sizes reported in animal studies. However, the average infarct size in the REVIVAL-3 study was approximately 27% to 28%, and erythropoietin still was not effective in reducing infarct size. In addition, the doses of erythropoietin used in animal studies (3000-5000 U/kg) were generally higher than those used in the current and other clinical studies. However, the cardio-protective effects of erythropoietin have been demonstrated at doses as low as 150 U/kg in rodents (when administered ≤4 hours of ischemic injury). Importantly, animal studies indicate that there is a therapeutic window of time beyond which the tissue-protective effects of erythropoietin are attenuated; furthermore, the duration of this window is directly related to erythropoietin dose. For example, in a rodent model of coronary ligation, the benefits of erythropoietin at 3000 U/kg can still be observed when administration is delayed up to 12 hours (but not 24 hours) after ischemic injury; whereas at 150 U/kg, these benefits are observed only when erythropoietin is administered within 4 hours (but not 8 hours) of ischemic injury. Furthermore, in a rodent model of ischemia reperfusion, an erythropoietin dose of 3000 U/kg was effective in reducing infarct size if administered at the time of reperfusion (after a 2-hour ischemic injury), but not if infused 4 hours later. In the REVEAL trial, erythropoietin was infused more than 6 hours (on average) after symptom onset. Thus, we cannot exclude the possibility that administration of erythropoietin in our study occurred beyond the putative therapeutic window. The delay in study medication infusion was related in part to the design of the REVEAL trial, which required successful PCI before randomization and was mindful of the importance of door-to-balloon times in patients with STEMI. Although it is possible that earlier administration could have affected the results, erythropoietin did not reduce infarct size in the REVIVAL-3 trial, even though it was administered at the time of PCI.

CONCLUSIONS

In summary, a single bolus of 60 000 U of epoetin alfa in patients with STEMI within 4 hours following successful PCI did not reduce infarct size and was associated with higher rates of adverse cardiovascular events. Subgroup analyses in our study raised concerns about an increase in infarct size among the small number of patients who were aged 70 years or older.

**Author Affiliations:** Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, Maryland (Dr Najjar, Talan, Ferucci, Longo, and Lakatta); MedStar Health Research Institute, Washington, DC (Dr Najjar); Division of Cardiology, Department of Medicine, Duke University School of Medicine (Drs Rao, Melloni, Povsic, Patel, Kim, and Harrington) and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina (Drs Rao, Melloni, Povsic, Melton, Hasselblad, Patel, and Harrington and Mss Prather and Kilmar); Division of Cardiovascular Medicine, Ohio State University, Columbus (Dr Raman); Mayo Clinic, Rochester, Minnesota (Dr Barsness); New York Methodist Hospital, Brooklyn (Dr Heitner); Division of Cardiology, SUNY- Stony Brook University Medical Center, Stony Brook, New York (Dr Gruber); and Division of Cardiology, Henry Ford Health System, West Bloomfield, Michigan (Dr Greenbaum).

**Author Contributions:** Dr Najjar had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Study concept and design:** Najjar, Rao, Povsic, Melton, Patel, Kim, Talan, Ferucci, Longo, Lakatta, Harrington.

**Acquisition of data:** Najjar, Raman, Povsic, Melton, Prather, Heitner, Gruber, Greenbaum, Patel, Kim, Longo, Harrington.

**Analysis and interpretation of data:** Najjar, Melloni, Raman, Povsic, Melton, Barsness, Prather, Kilmar, Hasselblad, Kim, Longo, Lakatta, Harrington.

**Drafting of the manuscript:** Najjar, Prather, Hasselblad, Lakatta.

**Critical revision of the manuscript for important intellectual content:** Najjar, Raman, Melloni, Povsic, Melton, Barsness, Prather, Heitner, Kilmar, Gruber, Greenbaum, Patel, Kim, Talan, Ferucci, Longo, Lakatta, Harrington.

**Statistical analysis:** Prather, Kilmar, Hasselblad, Lakatta.

**Obtained funding:** Najjar, Povsic, Longo, Lakatta, Harrington.

**Administrative, technical, or material support:** Najjar, Rao, Melton, Gruber, Kim, Longo, Harrington.

**Study supervision:** Najjar, Rao, Melloni, Raman, Prather, Heitner, Melton, Kim, Longo, Harrington.

**Conflict of Interest Disclosures:** All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Najjar reported receiving research funding from HeartWare. Dr Rao reported receiving research funding from Novartis, Cordis Corporation, and Ikaria; and being a consultant for sanofi-aventis, Bristol-Meyers Squibb, AstraZeneca, Daichi Sankyo-U.S.A, and Dr Raman reported receiving grant support from the National Institutes of Health and from Siemens Corporation. Dr Povsic reported receiving grants from Baxter International, Regado Biosciences, and Theravance. Dr Barsness reported being a consultant for Gilead Sciences Inc and receiving travel compensation from Novartis Pharmaceuticals Corporation. Dr Heitner reported that New York Methodist Hospital received compensation for his work as a principal investigator for a study; receiving compensation for his expert testimony in an individual malpractice case; receiving grant support from the Empire Clinical Research Investigators Program; and receiving compensation for serving on a steering committee for a trial. Dr Hasselblad reported receiving salary support via grants from Eli Lilly and Medicare Inc administered through Duke University. Dr Greenbaum reported receiving compensation from various law firms for expert testimony; compensation for serving on speakers bureaus for various companies; and owning stock or stock options in various other device and health care companies. Dr Patel reported being a board member for Genzyme’s advisory board and Bayer Healthcare; and serving as a consultant for Ikaria. Dr Kim reported being an inventor on a US patent for Delayed Enhancement MRI, which is owned by Northwestern University. Dr Harrington reported that a complete listing of disclosure information is available at https://dcri.org/about-us/conflict-of-interest/Harrington-COI_2010.pdf. None of the other authors reported disclosures.

**Funding/Support:** This study was supported by Intramural Research Program contract HHS-N-260-2005-00010-C from the National Institute on Aging.

**Role of Sponsor:** The Duke Clinical Research Institute served as the coordinating center under contract from the National Institute on Aging. Investigators from the National Institute on Aging and the Duke Clinical Research Institute collaborated in designing and supervising the conduct of the study. Neither Centocor Ortho Biotech nor Florida Biologix provided funding or had input into the design or conduct of the study nor any input into data collection, data analysis, or the writing of the manuscript.

**REVEAL Data and Safety Monitoring Board:** Lawrence J. Appel, MD, MPH (chair), Victor Ferrari, MD, Mark D. Kelemen, MD, MSc, Jon R. Resar, MD, Michael L. Tetzlaff, MD, and Edgar R. Miller III, MD, PhD (secretary).

**Previous Presentations:** Primary findings were presented at the American Heart Association Annual Meeting; November 17, 2010; Chicago, Illinois.

**Online-Only Material:** The eAppendix and eTable 1 and eTable 2 are available at http://www.jama.com.

**Additional Contributions:** We thank the members of the REVEAL data and safety monitoring board. All of the data and safety monitoring board members received an honorarium for their services from the National Institute on Aging. We also thank Jonathan McCall, BA, of the Duke Clinical Research Institute (Durham, North Carolina), who provided editorial assistance with the manuscript as part of his regular duties as a medical editor. Mr McCall is a salaried employee of the Duke Clinical Research Institute.

**REFERENCES**


2. McGovern PG, Pankow JS, Shahar E, et al; Minnesota Heart Survey Investigators. Recent trends in...


